Trial Profile
Lirilumab (Anti-KIR mAb) Combined With Rituximab for Relapsed, Refractory or High-risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Lirilumab (Primary) ; Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 16 Aug 2019 Status changed from active, no longer recruiting to completed.
- 17 May 2019 Planned End Date changed from 1 Jun 2021 to 1 Jun 2022.
- 20 Jun 2017 Status changed from recruiting to active, no longer recruiting.